SEGMENT INFORMATION

12 Months Ended

Oct. 31, 2021

Segment Reporting [Abstract]

SEGMENT INFORMATION

9.    SEGMENT INFORMATION

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) our legacy Cancer Diagnostics activities and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the years ended October 31, 2021 and 2020:

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

	Year Ended October 31,
	2021			2020
Net income/(loss):
CAR-T Therapeutics	$	(5,672,622	)	$	(2,241,443	)
Cancer Vaccines		(4,558,811	)		(828,136	)
Anti-Viral Therapeutics		(2,927,979	)		(1,168,969	)
Cancer Diagnostics		(78,067	)		(5,836,594	)
Patent Licensing		109,556			(17,221	)
Total	$	(13,127,923	)	$	(10,092,363	)
Total operating costs and expenses	$	13,648,192		$	9,978,202
Less non-cash share-based compensation		(8,058,078	)		(4,137,460	)
Operating costs and expenses excluding non-cash share-based compensation	$	5,590,114		$	5,840,742
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics	$	2,421,487		$	1,141,542
Cancer Vaccines		1,641,977			365,681
Anti-Viral Therapeutics		1,080,279			739,140
Cancer Diagnostics		49,170			3,581,377
Patent Licensing		397,201			13,002
Total	$	5,590,114		$	5,840,742

	October 31,
	2021		2020
Total assets:
CAR-T Therapeutics	$	15,067,933	$	2,988,124
Cancer Vaccines		13,276,518		946,923
Anti-Viral Therapeutics		7,368,214		2,464,361
Cancer Diagnostics		391,618		2,869,529
Patent Licensing		153,121		184,027
Total	$	36,257,404	$	9,452,964

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

The Company’s consolidated revenue of $512,500 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,002, for the year ended October 31, 2021 were solely related to our patent licensing segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.